Integer (NYSE:ITGR – Get Free Report) was upgraded by Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports. The firm currently has a $115.00 price target on the medical equipment provider’s stock. Oppenheimer’s price target would suggest a potential upside of 35.06% from the company’s previous close.
ITGR has been the topic of a number of other reports. Wall Street Zen lowered Integer from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Citigroup dropped their target price on Integer from $92.00 to $89.00 and set a “neutral” rating on the stock in a research report on Friday, May 1st. Piper Sandler restated an “overweight” rating and issued a $97.00 target price (up from $87.00) on shares of Integer in a research note on Friday, May 1st. Raymond James Financial reiterated an “outperform” rating and issued a $101.00 price objective on shares of Integer in a report on Monday, February 23rd. Finally, Zacks Research lowered shares of Integer from a “hold” rating to a “strong sell” rating in a research report on Monday. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $100.38.
Check Out Our Latest Stock Report on Integer
Integer Stock Performance
Integer (NYSE:ITGR – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). The company had revenue of $439.58 million for the quarter, compared to analyst estimates of $426.48 million. Integer had a return on equity of 12.83% and a net margin of 7.64%.The company’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.31 earnings per share. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. On average, analysts forecast that Integer will post 6.11 EPS for the current fiscal year.
Insider Activity
In other news, VP Tommy P. Thomas sold 825 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $85.00, for a total value of $70,125.00. Following the completion of the sale, the vice president directly owned 4,381 shares of the company’s stock, valued at $372,385. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ITGR. William Blair Investment Management LLC acquired a new position in shares of Integer in the third quarter valued at $28,459,000. Public Sector Pension Investment Board boosted its holdings in shares of Integer by 14.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 136,632 shares of the medical equipment provider’s stock worth $14,118,000 after buying an additional 17,699 shares during the period. New York State Common Retirement Fund grew its stake in Integer by 12.0% in the 3rd quarter. New York State Common Retirement Fund now owns 267,613 shares of the medical equipment provider’s stock valued at $27,652,000 after buying an additional 28,650 shares during the last quarter. Magnetar Financial LLC bought a new position in Integer in the 3rd quarter valued at about $1,890,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in Integer during the third quarter worth approximately $41,938,000. 99.29% of the stock is owned by institutional investors and hedge funds.
About Integer
Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.
Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.
See Also
- Five stocks we like better than Integer
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.
